Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): Results of a prospective randomized study

Esteban, Emilio; Sande, J. De; Villanueva, N.; Corral, Norberto; Muñiz, I.; Vieitez, José María; Fra, J.; Fernández, Yolanda; Estrada, Enrique; Fernández, J Letéllez; Luque, M.; Jimenez, P.; Mareque, B.; Capellan, M. Sevillano; Buesa, J. M.; Lacave, Ángel J.

doi:10.1016/j.lungcan.2006.09.021

Cited by 7 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our survival rates -more than 1-year overall survival and more than 50% 1-year survival rates -indicate a highly effective schedule. Docetaxel-containing secondand even third-line antineoplastic drugs may have con- layed administration when the platelet count was below 100×10 9 /L -1 , but some authors have administered gemcitabine with 18 or without 17 reduced doses when the platelet count was above 75×10 9 /L -1 . If we had done this, our delay rates would have been much lower.…”

Section: Discussionmentioning

confidence: 99%

Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8

Akçalı

Çalıkuşu

Sakallı

et al. 2008

Tumori

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8

Akçalı

Çalıkuşu

Sakallı

et al. 2008

Tumori

View full text Add to dashboard Cite

show abstract

“…Third-generation three-drug protocols have previously been tried in small trials in the setting of stage 3 NSCLC [27,28]. Gemcitabine, vinorelbine, cisplatin (GVP) particularly, appear to be promising among these regimens, with a pathological complete response rate of 25% [27].…”

Section: Discussionmentioning

confidence: 99%

“…Gemcitabine, vinorelbine, cisplatin (GVP) particularly, appear to be promising among these regimens, with a pathological complete response rate of 25% [27]. Therefore, future RCTs using these three-drug protocols for NCT are warranted.…”

Section: Discussionmentioning

confidence: 99%

The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis

2012

View full text Add to dashboard Cite

BackgroundAlthough neoadjuvant chemotherapy (NCT) is widely used, it is not clear which subgroup of locally advanced non-small-cell lung cancer (NSCLC) patients should be treated with this approach, and if a particular benefit associated with NCT exists. In this study, we aimed to investigate the potential correlates of benefit from NCT in patients with NSCLC.MethodsAll randomized clinical trials (RCTs) utilizing a NCT arm (without radiotherapy) versus a control arm before surgery were included for metaregression analysis. All regression analyses were weighed for trial size. Separate analyses were conducted for trials recruiting patients with different stages of disease. Previously published measures of treatment efficacy were used for the purpose of this study, regardless of being published in full text or abstract form.ResultsA total of 14 RCTs, consisting of 3,615 patients, were selected. Histology, stage, various characteristics of the NCT protocol, and different trial features including trial quality score were not associated with the benefit of NCT. However, in trials of stage 3 disease only, there was a greater benefit in terms of reduction in mortality from NCT, if protocols with three chemotherapeutics were used (B = −0.18, t = −5.25, P = 0.006).ConclusionsWe think that patients with stage 3 NSCLC are served better with NCT before surgery if protocols with three chemotherapy agents or equally effective combinations are used. In addition, the effect of neoadjuvant chemotherapy is consistent with regard to disease and patient characteristics. This finding should be tested in future RCTs or individual patient data meta-analyses.

show abstract

“…After full and further assessment of the remaining 2,138 articles, 891 noncohort studies, 599 studies irrelevant to NSCLC, 628 studies irrelevant to chemotherapy, and 1 study without complete data were further excluded. Finally, 19 RCTs were considered eligible to be enrolled in the current NMA 19,22,[29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45] (Figure 1). There were 4,322 patients with advanced NSCLC, the majority of who received the chemotherapy regimen of carboplatin + gemcitabine.…”

Section: Baseline Characteristics Of Included Studiesmentioning

confidence: 99%

Short‐Term Efficacy of Different First‐Line Chemotherapy Regimens for Advanced Non‐Small Cell Lung Cancer: A Network Meta‐Analysis

Zhang

Zhu

Tao

et al. 2020

Clinical Translational Sci

View full text Add to dashboard Cite

This study intends to compare short-term efficacy of 12 chemotherapy regimens in treatment of advanced non-small cell lung cancer (NSCLC) by a network meta-analysis (NMA). PubMed, Cochrane Library, and Embase were searched from the inception of each database to June 2018. Randomized controlled trials (RCTs) of the 12 chemotherapy regimens for advanced NSCLC were included. Direct and indirect evidence were combined by NMA to evaluate the odds ratio and the surface under the cumulative ranking curves (SUCRA) of the 12 chemotherapy regimens. Nineteen RCTs that met our inclusion criteria were collected in this study. For partial response (PR), gemcitabine exhibited relatively poor efficacy compared with cisplatin + gemcitabine, carboplatin + gemcitabine, carboplatin + paclitaxel, paclitaxel + gemcitabine, and cisplatin + gemcitabine + vinorelbine. For overall response rate (ORR), gemcitabine had poorer efficacy than cisplatin + gemcitabine and paclitaxel + gemcitabine. For disease control rate (DCR), compared with carboplatin + gemcitabine and gemcitabine, paclitaxel + gemcitabine had a better efficacy. Gemcitabine had the lowest SUCRA values in terms of complete response, PR, ORR, stable disease, and DCR; whereas paclitaxel + gemcitabine ranked the highest in ORR, progressive disease, and DCR. The cluster analysis revealed that cisplatin + gemcitabine, paclitaxel + gemcitabine, and cisplatin + gemcitabine + vinorelbine had better short-term efficacy for advanced NSCLC. Collectively, short-term efficacy of multidrug combination chemotherapy regimens was superior to that of single-drug chemotherapy regimens for advanced NSCLC. Cisplatin + gemcitabine, paclitaxel + gemcitabine, and cisplatin + gemcitabine + vinorelbine may have particularly prominent short-term efficacy for advanced NSCLC.Non-small cell lung cancer (NCLSC) accounts for about 85% of lung cancers, with 5-year survival rates of 15.9%. 1 It was reported that nearly 75% of patients with NSCLC presented with the advanced-stage disease because obvious symptoms were absent from its early stage. 2 Environmental factors, like smoking, radon, and asbestos, as well as some internal genetic factors, have been suggested as possible etiological factors of NSCLC. 3 Currently, the main treatments for this disease include surgery, platinum-based chemotherapy, radiotherapy, molecular targeted therapy, and cell biological therapy. 4,5 Even though great advances have been achieved in lung cancer screening, diagnostics, and therapy since the last century, it is extremely significant to understand the application of NSCLC therapies and outcomes in clinical practice. 6 Currently, platinum drugs are recognized as one of the accesses to prolong survival of patients with advanced NSCLC. 7 It interferes with the DNA replication by the electrophilic effect

show abstract

Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): Results of a prospective randomized study

Cited by 7 publications

References 41 publications

Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8

Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8

The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis

Short‐Term Efficacy of Different First‐Line Chemotherapy Regimens for Advanced Non‐Small Cell Lung Cancer: A Network Meta‐Analysis

Contact Info

Product

Resources

About